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cense.Abstract Aim(s) of the work: To explore early changes in the predictors of bone turnover in chil-
dren with juvenile idiopathic arthritis (JIA). To identify osteoprotegerin/receptor activator of
nuclear factor-jB ligand (OPG/RANKL) ratio in the serum of the same patients and its relation
to the parameters of joint inﬂammation and joint destruction.
Patients and methods: Seventy children with JIA and 30 healthy children individually matched
for age, sex, race, and county of residence were included in this study. Serum levels of calcium
(Ca), phosphorus (Ph), alkaline phosphatase (ALP), osteocalcin (OC), RANKL and (OPG) were
measured. Urinary concentration of deoxypyridinoline (DPD) was also done. All involved joints
were assessed by plain radiography.
Results: Signiﬁcant low serum concentrations of ALP and OPG was observed in JIA group,
while there was a signiﬁcant increase in serum level of RANKL and urine level of DPD compared
to controls. OPG/RANKL ratio was signiﬁcantly lower in JIA patients than in controls. OPG/2243435.
m (E.A.M. Alkady).
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218 E.A.M. Alkady et al.RANKL ratio is correlated with most clinical characteristics, disease activity variables, JIA out-
come measures and radiographic ﬁndings. DPD, RANKL and OPG/RANKL ratio, respectively,
are considered as independent predictors of juxta-articular osteoporosis. OPG/RANKL ratio
was the only predictor of bone erosion.
Conclusion: The OPG/RANKL ratio could be an early predictor of increased bone resorption
and a valuable biomarker for joint inﬂammation and bone injury in JIA patients.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
In juvenile idiopathic arthritis (JIA), a decrease in bone mass
has been described in a high percentage of children with in-
creased risk of osteoporosis [1]. The decrease in bone mass is
multifactorial in origin [2] and correlates with the duration
of active disease and the number of affected joints [1]. Osteo-
porosis is characterized by loss of bone mass associated with
increased fragility and risk of fractures [3]. It is diagnosed by
measuring a real bone mineral density (BMD, g/cm2) [4].
BMD in JIA is inﬂuenced by several factors as inﬂamma-
tion, medication, nutrition, and physical inactivity. It is impor-
tant to detect the early changes of bone mass in JIA in order to
identify patients at risk to develop reduced bone mass and
osteoporotic fracture [5]. Dual energy X-ray absorptiometry
(DEXA) is the preferred method for measuring bone mass in
children [6].
Bone strength is compromised if bone remodeling favors
resorption by osteoclasts over bone formation by osteoblasts
[7]. Understanding the regulation of bone remodeling and
detection of the early changes of bone predictors holds the
key to the management of osteoporosis [8].
Biochemical markers of bone turnover are indirect indices of
skeletal metabolism. A range of biochemical markers have been
investigated for applicability to determine bone health in chil-
dren with JIA [9]. However, good markers in children need
more investigations [10]. Osteocalcin (OC) is the major non
-collagenous protein of the bone matrix. OC is predominantly
synthesized by mature osteoblasts and is mainly incorporated
into the bone matrix. The circulating level of OC (10–25%) re-
ﬂects the rate of bone formation [9]. Deoxypyridinoline (DPD)
is one of two major cross-links in the collagen molecule. It is ex-
creted in the urine and is considered a bone speciﬁc resorption
marker [11].
Tumor necrosis factor (TNF) was identiﬁed as the main
inﬂammatory pathogenic mediator for chronic arthritis [12].
Among the TNF family, the receptor activator of nuclear fac-
tor-jB (RANK), RANKL, and osteoprotegerin (OPG) are in-
volved in many immunological and skeletal diseases
characterized by bone resorption including inﬂammatory
arthritis [13].
Recent data have indicated overlapping pathways between
bone biology and biology of inﬂammation giving the impres-
sion that inﬂammation may have a role in pathology of osteo-
porosis [7]. RANKL is a type II homotrimeric transmembrane
protein produced by osteoblastic lineage cells and T lympho-
cytes, and synoviocytes. It stimulates the receptor RANK pres-
ent in dendritic cells and osteoclasts besides increasing survival
and immune activation of dendritic cells. It promotes osteo-
clast formation, differentiation, activation, and survival lead-
ing to enhanced bone resorption [14].Osteoprotegerin (OPG), a soluble protein synthesized by
osteoblasts, acts as a soluble receptor that binds to RANKL
and preventing its binding to RANK with a consequent de-
crease in osteoclast activation and function [15]. Therefore,
RANKL and OPG act as key regulators of bone metabolism
and osteoclast biology. OPG/RANKL ratio is an important
determinant of bone mass and skeletal integrity [14].
The aim of this study was to explore the early changes in
the predictors of bone turnover (osteocalcin, deoxypyridino-
line, alkaline phosphatase, the receptor activator of nuclear
factor-jB ligand and osteoprotegerin) in children with juvenile
idiopathic arthritis (JIA), without clinical symptoms and/or
radiological signs of osteoporotic fractures. To identify the
expression of OPG/RANKL ratio in the serum of the same pa-
tients and comparing it to the parameters of joint inﬂamma-
tion and joint destruction.
2. Patients and methods
Seventy patients with JIA (32 boys and 38 girls) according to
the International League of Associations for Rheumatology
(ILAR) criteria [16] were consecutively selected from Rheuma-
tology and Rehabilitation Department, Assiut University
Hospital, for the study. Thirty apparently healthy children
matched with the patients according to age, sex, ethnicity,
average dietary intake, average sun exposure and geography
were recruited as controls. The geographic match may reduce
a bias caused by geographic differences in BMD and fracture
rates related to environmental factors or genetic risk determi-
nants [17]. Regarding patients’ medication, patients were tak-
ing one of the following disease-modifying antirheumatic
drugs: methotrexate, hydroqauine, sulfasalazine, azathioprine,
leﬂonamide or combination therapy and 48 patients (68.6%)
were receiving corticosteroids.
Children excluded from the study were those older than 16
years and younger than 4 years, Children with any clinical or
radiological ﬁnding of osteoporosis, with secondary causes of
low bone mass, such as a clinical history of rickets, hypopara-
thyroidism, hyperthyroidism or hypothyroidism, poor gastro-
intestinal absorption, and renal or hepatic insufﬁciency.
Informed consent was obtained from all children’s parents
or their relatives. The study protocol was approved by ethical
committee of Faculty of Medicine, Assiut University.
2.1. Data collection
Demographic, clinical and anthropometric data for patients
and controls were obtained through complete medical history,
physical and articular examinations. All participants com-
pleted a translated Arabic form of self reported questionnaires
[18] about fractures and leisure-time physical activities outside
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[19,20] were obtained from all patients. The joint index used
was the whole 71 joint count [21].
The physician’s global assessment of overall disease activity
and patient/parent’s global assessment of child’s well-being on
a 100-mm visual analog scale (VAS) and patient/parent’s
assessment of child’s functional ability through the Childhood
Health Assessment Questionnaire (CHAQ) were recorded [22].
2.2. Laboratory assessments
Complete blood picture (CBC), erythrocyte sedimentation rate
(ESR), and rheumatoid factor (RF), antistreptolycin O titer
(ASOT) and antinuclear antibodies (ANA) were done to all
patients.
Five milliliters of venous blood was obtained from all indi-
viduals included in the study and put into a water bath for
15 min and was centrifuged at (4000 rpm). Then serum was
separated and kept stored at 20 C until analysis, to deter-
mine the following bone markers:
(1) Serum level of calcium (Ca), phosphorus (Ph) and alka-
line phosphatase (ALP).
(2) Serum level of osteocalcin (OC) using – ELISA kit (Bio-
source, Europe, SA) which is a quantitative sandwich
enzyme linked immuno-sorbent assay.
(3) Serum RANKL (sRANKL) levels was estimated by
using ELISA kit, (Biomedica Group, Biomedica Medi-
cine Product, GmbH and Co., Cat. No. BI-20422H). It
is an enzyme immunoassay for the quantitative determi-
nation of RANKL in serum.
(4) Serum Osteoprotegerin (OPG) using ELISA technique
(Biovendor Laboratory Medicine, Inc., Czech Republic),
Cat. No. RD 194003200. It is a biotin labeled antibody
based sandwich enzyme immunoassay.
Urine samples (preservative ﬁrst or secondary morning
voids urine) were taken from all children enrolled in the study
and stored at 20 C for determination of deoxypyridinoline
(DPD). Urinary DPD concentration was measured by ME-
TRA DPD EIA kit, Cat. No. 8007. METRA DPD assay is a
competitive enzyme immunoassay, in microtiter strip-well for-
mat utilizing a monoclonal anti-DPD coated on the strip to
capture DPD in the sample and compete with conjugate
DPD alkaline phosphatase for antibody and the reaction is de-
tected with substrate. METRA DPD results were corrected for
urinary concentration by creatinine in urine.
2.3. Radiological assessments
Conventional ﬁlm screen radiographs of all affected joints
were obtained. The features evaluated as absent or present.
Radiographic evaluation was performed by the concordance
of two physicians who are experts in the osteoarticular system.
Statistics: The data were coded and entered using the statis-
tical package for the Social Science Program (SPSS) version
15. The data were summarized using descriptive statistics:
mean ± standard deviation (±SD), or frequencies (n) and
percentages (%). Statistical differences between groups were
tested using unpaired sample t-test. Within the patients’ co-
hort, differences were tested either by independent sample
t-test or by one-way analysis of variance (ANOVA). Multipleforward logistic regression analysis was performed to identify
the independent predictors for osteoporosis, bone erosion
and new bone formation. In all cases p 6 0.05 was considered
statistically signiﬁcant.
3. Results
The main demographic and anthropometric characteristics
of JIA patients and healthy controls are summarized in
Table 1. Weight bearing physical activities were lower in JIA
patients when compared with control (p= 0.03). The clinical,
laboratory and radiological characteristics of patients with JIA
are presented in Tables 2 and 3.
The serological markers of bone turnover in patients with
JIA and healthy control are summarized in Table 4. There
was a signiﬁcant decrease in the serum level of total ALP
(p= 0.001), serum level of OPG (p= 0.000) and the OPG/
RANKL ratio was signiﬁcantly lower (p= 0.000) in JIA pa-
tients than in control group. There was a signiﬁcant increase
in the serum level of RANKL (p= 0.000) and in the urine level
of DPD (p= 0.000) in JIA patients compared with controls.
Table 5 showed the relationship between the laboratory
predictors of osteoporosis and the parameters of joint inﬂam-
mation and joint destruction in the JIA patients. The OPG/
RANKL ratio is correlated with the clinical characteristics of
the disease and with JIA outcome measures. Moreover, it is
correlated with the medication use, weight bearing physical
activities and with most of the radiographic ﬁndings.
Multiple forward logistic regression analysis showed that
DPD, s.RANKL and OPG/RANKL ratio (95% CI; 1.003–
1.013, 0.661–0.996 and 0.855–0.974), respectively, are consid-
ered as independent predictors of juxta-articular osteoporosis
and OPG/RANKL ratio (95% CI; 0.998–1.030) was the only
independent predictor of bone erosion. OC and s.RANKL
(95% CI; 1.115–1.656 and 0.509–1.026), respectively, were
independent predictors of new bone formation.
4. Discussion
JIA strongly affects the skeletal system in certain patients,
which may lead to either localized or generalized osteoporosis
[1]. Osteoporosis in the pediatric age group carries little mor-
tality; however, it does bring a considerable burden of morbid-
ity especially due to pain, interference with regular activities,
associated fractures risk and long-term sequels [23].
In this study, the anthropometric measurements of JIA pa-
tients showed no signiﬁcant difference when compared with the
control group. These results were similar to the results of Lien
et al. [5] but were contradictory to the results of Kandil et al. [7]
who reported that there was an altered body composition in
JIA patients with a higher total body fat percentage approach-
ing signiﬁcance when compared with the healthy children. They
related that probably to chronic inﬂammation and reduced
physical activity, which means that the muscle force applied
to bone, is diminished and may result in a low bone mass.
Regarding the biochemical markers of bone turnover in this
group of JIA patients, there was a signiﬁcant increase in the ur-
ine level of DPD compared with controls indicating increased
bone resorption among those patients. This is consistent with
the results of Kandil et al. [7] but in contrast to the results
of Pepmueller et al. [24]. However, no signiﬁcant difference
in the serum level of OC as a marker of bone formation among
Table 2 Clinical and laboratory characteristics of patients
with JIA.
Characteristics, no. (%) or mean ± SD JIA patients
Disease subtype
Systemic 21 (30%)
Oligoarthritis 10 (14.3%)
Polyarthritis, RF negative 6 (8.6%)
Polyarthritis, RF positive 9 (12.9%)
Enthesitis related arthropathy 19 (27.1%)
Psoriatic arthritis 5 (7.1%)
Disease duration 49 ± 28, 35
Morning stiﬀness 72.86 ± 56, 83
Disease activity measures
No. of swollen joints 3.63 ± 5.78
No. of tender joints 12.16 ± 14.78
No. of joints with active arthritis 4.57 ± 6.21
ADSS 22.1 ± 24.54
Physician’s global assessment
of disease severity
31.57 ± 26.49
Patients/parent’s global assessment
of child’s well-being
31.64 ± 26.11
Childhood Health Assessment
Questionnaire (CHAQ)
0.91 ± 0.72
Disability index 55 (78.6%)
DMARDs
Previous/current use 48 (68.6%)
Total duration of use (months) 25.81 ± 25.94
Oral corticosteroids (CS)
No. of patients receiving CS (%) 48 (68.6%)
Dosage, mean ± SD (mg/day) 7.64 ± 8.97
Total duration of use (months) 19.01 ± 26.18
Laboratory
CRP (mg/dl) (positive =>12) 36 (51.4%)
HB level 11.3 ± 1.6
RF (IgM) (positive =>40 U) 10 (14.3%)
ANA 11 (15.7%)
ASOT (positive) 19 (27.1%)
ADSS: Articular Disease Severity Score, DMARDs: disease-mod-
ifying antirheumatic drugs, no: number, CRP: C-reactive protein,
HB: hemoglobin, RF: rheumatoid factor, ANA: antinuclear anti-
body, ASOT: antistreptolycin O titer.
Table 1 Demographic, anthropometric data, physical activity and fracture history of the studied groups.
Variables, no. (%) or mean ± SD JIA patients Controls p value
Total no. 70 30
Female/male no. 38/32 16/14
(%) (54.3/45.7) (53.3/46.7)
Age (years) 11.81 ± 3.37 12.28 ± 3.74 0.7
BMI (kg/m2) 18.56 ± 6.51 17.47 ± 3.31
Wt. bearing physical activity 54 (77.1%) 30 (100%) 0.03
Fracture history 10 (14.3%) 2 (6.7%) 0.7
no: number, BMI: body mass index, Wt: weight.
Table 3 Radiological abnormalities in patients with JIA.
Characteristics No. (%)
Soft tissue swelling 23 (32.9%)
Juxta articular osteopenia 30 (42.9%)
Narrow joint spaces 40 (57.1%)
Erosion 32 (45.7%)
Deformities 31 (44.3%)
New bone formation 6 (8.6%)
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Brik et al. [25] and Falcini et al [26]. Kandil et al. [7] found that
the serum level of OC was signiﬁcantly lower in JIA patients
compared to healthy control.ALP has been widely used as a marker of bone formation
but it lacks sensitivity and speciﬁcity [27]. In our group of
JIA patients, there was a signiﬁcant decrease in the serum level
of total ALP in contrast to Falcini et al. [26]. This may be ex-
plained by the fact that 80% of the total serum ALP in chil-
dren is derived from bone [28].
We demonstrated that there was a signiﬁcant decrease in
the serum level of OPG while the serum level of RANKL
showed a signiﬁcant increase and the OPG/RANKL ratio
was signiﬁcantly lower in JIA patients compared to the control
group. This is in accordance with Lien et al. [29]. These ﬁnd-
ings suggest an inadequate compensatory mechanism to bal-
ance the increase of RANKL indicating that these
alterations may reﬂect bone damage in this disease. The uni-
form moderate to high disease activity in our patients is the
most likely explanation for elevated s.RANKL level because
proinﬂammatory cytokines and most of the osteoclastogenic
factors present in chronic inﬂammatory arthritic joints are
known to enhance RANKL expression in osteoblasts, acti-
vated T lymphocytes, activated synovial cells and function
indirectly through speciﬁc receptors on stromal-osteoblastic
cells [30,31]. Also, the glucocorticoid use in our patients
(68.6%) might be another explanation as it has an important
effect in bone cells; decreasing bone formation [32] and
increasing bone resorption. The glucocorticoids increase osteo-
clastogenesis due to increased expression of RANKL and re-
duced expression of OPG [33].
Several studies in the literatures demonstrated that chronic
inﬂammatory processes result in generalized bone-mass loss,
bone demineralization, and progressive radiological abnormal-
ities. The bone articular complications consist of juxtarticular
osteopenia, subchondral and marginal bone erosions [34].
Comparing our results to that of Kandil et al. [7], they found
that the serum level of OPG and RANKL were signiﬁcantly
elevated while the OPG/RANKL ratio was signiﬁcantly lower.
They explained that as a higher compensatory production of
OPG secondary to the marked increase in RANKL level with
shift of equilibrium.
Table 5 Relationship between OC, DPD, OPG, RANKL and OPG/RANKL ratio and the parameters of joint inﬂammation and
joint destruction in JIA patients.
Variables OC p value DPD p value OPG p value s.RANKL p value OPG/RANKL ratio p value
Disease duration 0.70 0.05 0.04 0.03 0.007
Morning stiﬀness 0.05 0.01 0.10 0.007 0.000
Swollen joints (no.) 0.49 0.30 0.12 0.13 0.013
Tender joints (no.) 0.15 0.07 0.03 0.70 0.000
Active arthritis (no.) 0.35 0.34 0.198 0.24 0.038
ADSS 0.17 0.18 0.002 0.38 0.000
Physician’s global assess. of dis. severity 0.51 0.14 0.19 0.54 0.000
Pts/parent’s global assess. of child’s 0.59 0.06 0.13 0.65 0.001
CHAQ (disability index) 0.42 0.04 0.28 0.57 0.001
DMARDs
Duration 0.1 0.1 0.9 0.09 0.001
Steroids
Duration 0.22 0.61 0.37 0.87 0.000
Dose (mg/day) 0.01 0.05 0.77 0.02 0.001
Wt. bearing phy. activity 0.97 0.16 0.8 0.19 0.05
Laboratory
CRP (mg/dl), positive 0.89 0.44 0.29 0.92 0.13
RF (IgM) positive 0.07 0.64 0.03 0.08 0.23
Radiographic criteria
Juxta articular OP 0.08 0.000 0.56 0.26 0.007
Erosion 0.41 0.54 0.69 0.02 0.002
Deformities 0.40 0.66 0.67 0.52 0.96
New bone formation 0.000 0.79 0.26 0.03 0.22
no.: number; assess.: assessment; dis.: disease; Pts: patients; Wt.: weight; phy.: physical; OP: osteoporosis.
Table 4 Laboratory parameters of bone metabolism in JIA patients and healthy controls.
Variables JIA patients Controls p value
Serum chemistry
Ca (mg/dl) 8.87 ± 0.54 9.07 ± 1.44 0.3
Ph (mg) 5 ± 1.63 4.8 ± .89 0.6
ALP (U/l) 149.52 ± 72 200.08 ± 74.39 0.001
OC (ng/ml) 8.9 ± 7 7.21 ± 6.28 0.4
OPG (pg/ml) 133.8 ± 261.7 722.50 ± 409.97 0.000
s.RANKL (pg/ml) 8.37 ± 4.43 2.20 ± .73 0.000
OPG/RANKL 32.02 ± 50.61 369.29 ± 215.41 0.000
Urine chemistry
DPD (nmol/l) (19–325) 367.23 ± 149.97 212.18 ± 93.96 0.000
Ca: total calcium, Ph: phosphorus, ALP: alkaline phosphatase, OC: osteocalcin, OPG: osteoprotegerin, s.RANKL: serum receptor activator of
nuclear factor-jB ligand, DPD: deoxypyridinoline.
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most of the factors that induce RANKL expression by osteo-
blasts. Although there are contradictory data, in general, up
regulation of RANKL is associated with down regulation or
lower induction of OPG and the ratio of RANKL to OPG
changes in favor of osteoclastogenesis. So, the osteoclast num-
bers and activity can increase if there is a change in the
RANKL/OPG ratio due to either an increase in the former
or a decrease in the latter or a change in both that leads to a
change in the ratio in favor of RANKL [14].
Predictors of changes in bone mass including the clinical
characteristics, disease activity variables, disease outcomemeasures, medication use, laboratory measurements and
radiographic ﬁndings were correlated with our serological
markers and we found that the OPG/RANKL ratio was signif-
icantly correlated with the most parameters of joint inﬂamma-
tion and joint destruction more than OPG, RANKL, OC or
DPD alone.
In this study, by using multiple forward logistic regression
analysis tests, DPD, s.RANKL and OPG/RANKL ratio,
respectively, were the major independent predictors of juxta-
articular osteopenia. OC and s.RANKL, respectively, were
found to be the independent predictors for new bone
formation. However, OPG/RANKL ratio alone is the single
222 E.A.M. Alkady et al.independent predictor of bone erosion and this was in agree-
ment with the results of Spelling et al. [30] who suggest that a
low OPG/RANKL ratio may reﬂect bone damage in a group
of polyarticular JIA patients with bone erosion. Many reports
in the literature have supported the assertion that the RANKL/
OPG ratio is a key regulator of bone metabolism [35,36].
In conclusion from our study, early changes in the predic-
tors of bone resorption can predict the high risk group of get-
ting osteoporosis in JIA. OPG/RANKL ratio could be a
valuable biomarker for joint inﬂammation, bone injury and
early predictor of bone resorption in JIA patients.References
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